Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was grante...
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT06603818
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Clinical Trial to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC
- Conditions
- Interventions
- First Posted Date
- 2024-09-04
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT06584071
Perioperative Immunotherapy for NSCLC (ECTOP-1030)
- Conditions
- Interventions
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT06572722
A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization
- Conditions
- Interventions
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 113
- Registration Number
- NCT06503250
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou City, China
🇨🇳The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
🇨🇳Tianjin First Central Hospital, Tianjin, China
A Study Evaluating Single-agent Inavolisib and Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT06496568
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇺🇸University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
Atezolizumab in Combination with Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Emory University
- Target Recruit Count
- 12
- Registration Number
- NCT06492954
- Locations
- 🇺🇸
Chilldren's Healthcare of Atlanta, Atlanta, Georgia, United States
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 310
- Registration Number
- NCT06488716
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion
- Conditions
- Interventions
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT06439485
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 54
- Registration Number
- NCT06416436
- Locations
- 🇺🇸
The University of Kansas Medical Center, Kansas City, Kansas, United States
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- NovoCure Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT06390059
- Locations
- 🇪🇸
University Hospital Vall d'Hebron, Barcelona, Spain
🇪🇸University Hospital Foundation Jimenez Diaz, Madrid, Spain
🇪🇸Clara Campal Comprehensive Cancer Center (CIOCC), Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.